LLY logo

Eli Lilly and Company

LLY
Healthcare|Drug Manufacturers - General|US
$1354.00
-10.73 (-0.79%)
DCF Value
$771.70
Tangible Book / Share
$13.81
Graham Number
$177.24
Cash / Share
$5.48
Next Earnings Report
Feb 3, 2027
EPS est. $11.20 · Revenue est. $24.58B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest May 8, 2026 (424B2). Possible dilution.

Upcoming Data Readouts (42)

Dec 2026
Est. completion
Chronic Kidney Disease
SGLT2 Inhibitors and Renal Anemia in Japan: RWD
NCT07063316n=15,000
Jan 2027
Est. completion
P1Diabetes Mellitus
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Feb 2027
Est. completion
P1Obesity
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
Mar 2027
Est. completion
P2Severe Hypertriglyceridemia
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Apr 2027
Est. completion
P1P2Carcinoma, Non-Small-Cell Lung
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
May 2027
Est. completion
Metastatic Breast Cancer
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
Jun 2027
Est. completion
P1Primary Myelofibrosis
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Jul 2027
Est. completion
P2Recurrent Endometrial Carcinoma
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jul 2027
Est. completion
P1Healthy
A Study of LY4226695 in Healthy Participants
Aug 2027
Est. completion
P3Obesity
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Aug 2027
Est. completion
P1Healthy
A Study of LY4302814 in Healthy Participants
Aug 2027
Est. completion
P1Healthy Volunteers
A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)
Nov 2027
Est. completion
P1Heart Failure
A Study of LY3971297 in Participants With Heart Failure
Nov 2027
Est. completion
P3Alzheimer Disease
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Dec 2027
Est. completion
P3Crohn's Disease
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Dec 2027
Est. completion
P3Obesity
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Dec 2027
Est. completion
P1P2Relapsed/Refractory Chronic Lymphocytic Leukemia
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Mar 2028
Est. completion
P1Healthy Volunteers
A Study of LY4178256 in Healthy Participants
Mar 2028
Est. completion
P3Obesity
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Mar 2028
Est. completion
P1Rheumatoid Arthritis (RA)
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

Awaiting Results (6)

Trials past primary completion date but still active — data readout may be imminent.

Aug 2026
P3
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722
Jun 2026
P3
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667
Jan 2026
P3
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359
Jun 2024
P2
A Study of Abemaciclib in Recurrent Glioblastoma
NCT02981940
Jul 2023
P1
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001
Mar 2019
P3
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
NCT02763566

SEC Filings (69)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 202610-QQuarterly reportDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Oct 19, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Oct 16, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Aug 5, 202610-QQuarterly reportDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Jul 30, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Jul 24, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 24, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 23, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 23, 202611-KDocumentIndex
Jun 2, 202625-NSEDocumentIndex
May 20, 20268-KMaterial eventDocumentIndex
May 11, 2026SDDocumentIndex
May 8, 2026424B2Offering prospectusDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
May 6, 2026FWPDocumentIndex
May 6, 2026424B2Offering prospectusDocumentIndex
Apr 30, 202610-QQuarterly reportDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 29, 2026PX14A6GDocumentIndex
Apr 20, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 31, 2026DFAN14ADocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 20, 2026DEFA14AProxy / shareholder voteDocumentIndex
Mar 20, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 6, 2026PRE 14AProxy / shareholder voteDocumentIndex
Feb 12, 202610-KAnnual reportDocumentIndex
Feb 4, 20268-KMaterial eventDocumentIndex
Jan 23, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 15, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Dec 9, 2025SC TO-T/ATender offerDocumentIndex
Nov 21, 20258-KMaterial eventDocumentIndex
Nov 7, 2025SC TO-TTender offerDocumentIndex
Oct 30, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 30, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 30, 202510-QQuarterly reportDocumentIndex
Oct 30, 20258-KMaterial eventDocumentIndex
Oct 24, 2025SC TO-CTender offerDocumentIndex
Oct 3, 2025SC 13G/APassive 5%+ stakeDocumentIndex